Table 4. Open in new tab MRI findings in...

SSc patients (n = 93)

SSc patients with ASM (n = 43)

SSc patients without ASM (n = 50)

P-value^c

Myocardial inflammation and fibrosis

↑ECV^a

31 (72)

21 (42)

0.010

Increased signal intensity in T2-weighted sequence^a

27 (63)

22 (44)

0.070

T2 mapping (↑T2 Relaxation time)^a

27 (63)

22 (44)

0.070

↑T1 Relaxation time^a

31 (72)

25 (50)

0.049

LGE presence^a

32 (74)

22 (44)

0.010

Fibrosis localization

Subepicardial^a

15 (35)

15 (30)

0.810

Midwall^a

26 (61)

16 (32)

0.020

Subendocardial^a

5 (12)

4 (8)

0.810

Insertion point fibrosis present^a

6 (14)

7 (14)

0.990

Pattern of fibrosis

Focal^a

10 (23)

7 (14)

0.330

Multifocal^a

15 (36)

9 (19)

0.220

Linear^a

3 (7)

5 (10)

0.600

Diffuse^a

7 (16)

3 (6)

0.220

LV/RV dimension and function

LV end-diastolic volume indexed, ml/m^2b

74.13 (14.34)

72.88 (17.27)

0.970

LV end-systolic volume indexed, ml/m^2b

36.34 (8.75)

37.32 (14.68)

0.970

LV dilatation^a

6 (14)

7 (14)

0.990

LVEF,% ^b

51.26 (6.61)

51.56 (9.37)

0.970

Impaired LVEF^a

26 (61)

22 (44)

0.880

Impaired RV ejection fraction^a

22 (51)

21 (42)

0.970

RV dilatation^a

7 (16)

6 (12)

0.970

Pericardial effusion^a

16 (37)

17 (34)

0.970

Table 4.

Open in new tab

MRI findings in scleroderma patients with and without ASM

SSc patients (n = 93)	SSc patients with ASM (n = 43)	SSc patients without ASM (n = 50)	P-value^c
Myocardial inflammation and fibrosis
↑ECV^a	31 (72)	21 (42)	0.010
Increased signal intensity in T2-weighted sequence^a	27 (63)	22 (44)	0.070
T2 mapping (↑T2 Relaxation time)^a	27 (63)	22 (44)	0.070
↑T1 Relaxation time^a	31 (72)	25 (50)	0.049
LGE presence^a	32 (74)	22 (44)	0.010
Fibrosis localization
Subepicardial^a	15 (35)	15 (30)	0.810
Midwall^a	26 (61)	16 (32)	0.020
Subendocardial^a	5 (12)	4 (8)	0.810
Insertion point fibrosis present^a	6 (14)	7 (14)	0.990
Pattern of fibrosis
Focal^a	10 (23)	7 (14)	0.330
Multifocal^a	15 (36)	9 (19)	0.220
Linear^a	3 (7)	5 (10)	0.600
Diffuse^a	7 (16)	3 (6)	0.220
LV/RV dimension and function
LV end-diastolic volume indexed, ml/m^2b	74.13 (14.34)	72.88 (17.27)	0.970
LV end-systolic volume indexed, ml/m^2b	36.34 (8.75)	37.32 (14.68)	0.970
LV dilatation^a	6 (14)	7 (14)	0.990
LVEF,% ^b	51.26 (6.61)	51.56 (9.37)	0.970
Impaired LVEF^a	26 (61)	22 (44)	0.880
Impaired RV ejection fraction^a	22 (51)	21 (42)	0.970
RV dilatation^a	7 (16)	6 (12)	0.970
Pericardial effusion^a	16 (37)	17 (34)	0.970

SSc patients (n = 93)	SSc patients with ASM (n = 43)	SSc patients without ASM (n = 50)	P-value^c
Myocardial inflammation and fibrosis
↑ECV^a	31 (72)	21 (42)	0.010
Increased signal intensity in T2-weighted sequence^a	27 (63)	22 (44)	0.070
T2 mapping (↑T2 Relaxation time)^a	27 (63)	22 (44)	0.070
↑T1 Relaxation time^a	31 (72)	25 (50)	0.049
LGE presence^a	32 (74)	22 (44)	0.010
Fibrosis localization
Subepicardial^a	15 (35)	15 (30)	0.810
Midwall^a	26 (61)	16 (32)	0.020
Subendocardial^a	5 (12)	4 (8)	0.810
Insertion point fibrosis present^a	6 (14)	7 (14)	0.990
Pattern of fibrosis
Focal^a	10 (23)	7 (14)	0.330
Multifocal^a	15 (36)	9 (19)	0.220
Linear^a	3 (7)	5 (10)	0.600
Diffuse^a	7 (16)	3 (6)	0.220
LV/RV dimension and function
LV end-diastolic volume indexed, ml/m^2b	74.13 (14.34)	72.88 (17.27)	0.970
LV end-systolic volume indexed, ml/m^2b	36.34 (8.75)	37.32 (14.68)	0.970
LV dilatation^a	6 (14)	7 (14)	0.990
LVEF,% ^b	51.26 (6.61)	51.56 (9.37)	0.970
Impaired LVEF^a	26 (61)	22 (44)	0.880
Impaired RV ejection fraction^a	22 (51)	21 (42)	0.970
RV dilatation^a	7 (16)	6 (12)	0.970
Pericardial effusion^a	16 (37)	17 (34)	0.970

Reported as n (%) and compared by χ² test.

Reported as mean (s.d.) and compared by t-test.

All P-values were corrected using the Benjamini–Hochberg correction method.

ASM: abnormal septal motion; ECV: extracellular volume; LGE: late gadolinium enhancement; LV: left ventricular; LVEF: left ventricular ejection fraction; RV: right ventricular.

This Feature Is Available To Subscribers Only